Assessment of Serum Uric Acid, Urea, and Glucose Levels and Associated Factors among Breast Cancer Patients Attending A Tertiary Hospital in Bahirdar, Ethiopia: A Comparative Cross-Sectional Study.
Breast cancer
Felege-Hiwot Hospital
Glucose
Serum Uric acid
Urea
Journal
Ethiopian journal of health sciences
ISSN: 2413-7170
Titre abrégé: Ethiop J Health Sci
Pays: Ethiopia
ID NLM: 101224773
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
18
06
2022
accepted:
05
08
2022
entrez:
7
12
2022
pubmed:
8
12
2022
medline:
15
12
2022
Statut:
ppublish
Résumé
Breast cancer is currently become a major public health problem in both developed and developing regions, it is one of the most common surgical problems in Ethiopia. Therefore, this study assessed serum uric acid, urea, and glucose levels and associated factors among benign, malignant breast cancer patients and apparently healthy women attending at Felege-Hiwot comprehensive Specialized Hospital. Hospital based comparative cross-sectional study was conducted among benign, malignant breast cancer patients and apparently healthy women attending at Felege-Hiwot Comprehensive Specialized Hospital. Out of 178 study participants 66 benign and 23 malignant fine needle aspirate cytology confirmed breast cancer patients and 89 apparently healthy women, included. Multivariable logistic regression models used to measure the strength of associations. A P value of < 0.05 was considered statistically significant. Majority of the study participants, 81(91%) controls, 55(83.3%) benign, and 17(73.9%) malignant cases were premenopausal. Serum glucose 144.47±74.35 and uric acid 6.84±2.54 levels were significantly elevated in malignant cases than control (p-value< 0.05). Patients with malignant status were 4.38 times more likely to have hyperglycemia (AOR=4.38, 95%CI: 1.98-19.97) and 5.53 times more likely have hyperuricemia (AOR=20.43-95% CI: 6.80-61.23), 4 times more likely to have uremia (AOR=4.09, 95% CI: 1.06-15.91) compared to apparently healthy women. Serum glucose, and uric acid levels were significantly higher in malignant and benign cases compared with apparently healthy women. Family history of breast cancer, body mass index, systolic hypertension, comorbidity, residence and menopausal status were significantly associated with hyperglycemia, uremia and hyperuricemia.
Sections du résumé
Background
UNASSIGNED
Breast cancer is currently become a major public health problem in both developed and developing regions, it is one of the most common surgical problems in Ethiopia. Therefore, this study assessed serum uric acid, urea, and glucose levels and associated factors among benign, malignant breast cancer patients and apparently healthy women attending at Felege-Hiwot comprehensive Specialized Hospital.
Methods
UNASSIGNED
Hospital based comparative cross-sectional study was conducted among benign, malignant breast cancer patients and apparently healthy women attending at Felege-Hiwot Comprehensive Specialized Hospital. Out of 178 study participants 66 benign and 23 malignant fine needle aspirate cytology confirmed breast cancer patients and 89 apparently healthy women, included. Multivariable logistic regression models used to measure the strength of associations. A P value of < 0.05 was considered statistically significant.
Results
UNASSIGNED
Majority of the study participants, 81(91%) controls, 55(83.3%) benign, and 17(73.9%) malignant cases were premenopausal. Serum glucose 144.47±74.35 and uric acid 6.84±2.54 levels were significantly elevated in malignant cases than control (p-value< 0.05). Patients with malignant status were 4.38 times more likely to have hyperglycemia (AOR=4.38, 95%CI: 1.98-19.97) and 5.53 times more likely have hyperuricemia (AOR=20.43-95% CI: 6.80-61.23), 4 times more likely to have uremia (AOR=4.09, 95% CI: 1.06-15.91) compared to apparently healthy women.
Conclusion
UNASSIGNED
Serum glucose, and uric acid levels were significantly higher in malignant and benign cases compared with apparently healthy women. Family history of breast cancer, body mass index, systolic hypertension, comorbidity, residence and menopausal status were significantly associated with hyperglycemia, uremia and hyperuricemia.
Identifiants
pubmed: 36475251
doi: 10.4314/ejhs.v32i6.16
pii: jEJHS.v32.i6.pg1183
pmc: PMC9692154
doi:
Substances chimiques
Urea
8W8T17847W
Uric Acid
268B43MJ25
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1183-1192Informations de copyright
© 2022 Lissane Seifu, et al.
Références
Free Radic Biol Med. 1993 Jun;14(6):615-31
pubmed: 8325534
Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):608-19
pubmed: 18600514
CA Cancer J Clin. 2019 May;69(3):211-233
pubmed: 30762872
S Afr Med J. 2019 Mar 29;109(4):264-271
pubmed: 31084693
Science. 2017 Nov 17;358(6365):941-946
pubmed: 29025995
Histopathology. 2020 Aug;77(2):181-185
pubmed: 32056259
Biomed Res Int. 2014;2014:761264
pubmed: 24587990
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
J Carcinog. 2006 May 11;5:14
pubmed: 16689993
Mod Pathol. 2010 May;23 Suppl 2:S60-4
pubmed: 20436504
Contrib Nephrol. 2005;147:47-60
pubmed: 15604605
Am Fam Physician. 2008 Dec 15;78(12):1361-6
pubmed: 19119554
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Afr Health Sci. 2010 Mar;10(1):9-13
pubmed: 20811518
Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1361-8
pubmed: 12433712
Breast Cancer Res. 2008;10(1):202
pubmed: 18304378
Clin Transl Med. 2012 Aug 15;1(1):16
pubmed: 23369448
Korean J Physiol Pharmacol. 2014 Feb;18(1):1-14
pubmed: 24634591
Immunol Rev. 2010 Jan;233(1):218-32
pubmed: 20193002
J Exp Clin Cancer Res. 2019 Jul 23;38(1):327
pubmed: 31337431
Br J Cancer. 2011 Aug 23;105(5):709-22
pubmed: 21772329
J Natl Cancer Inst. 1972 Mar;48(3):605-13
pubmed: 5058966
Asian Pac J Cancer Prev. 2015;16(2):675-8
pubmed: 25684506
J Cell Mol Med. 2015 Jul;19(7):1614-23
pubmed: 25753200
BMC Res Notes. 2015 Oct 11;8:553
pubmed: 26455633
Indian J Clin Biochem. 2015 Jan;30(1):11-26
pubmed: 25646037
Biomed Res Int. 2014;2014:461917
pubmed: 24864247
Cancer Treat Rev. 2012 Oct;38(6):698-707
pubmed: 22178455
Sci Adv. 2016 May 27;2(5):e1600200
pubmed: 27386546
Oncotarget. 2017 Aug 23;8(46):81462-81474
pubmed: 29113405